(Total Views: 398)
Posted On: 07/28/2021 7:47:06 AM
Post# of 653
$RLFTF $NRXP Geneva, Switzerland, July 28, 2021 – RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (“Relief”), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company of its collaboration partner, NRx Pharmaceuticals, Inc., (Nasdaq: NRXP) (“NRx”) reported in a press release yesterday that the Nation of Georgia's Prime Minister and Minister of Health have issued an Emergency Use Authorization for intravenous aviptadil for the treatment of critical COVID-19.
NRx also reported that the first doses of aviptadil will arrive in the Nation of Georgia within 24 hours, and discussions are underway with the Ministry of Health to provide access to ZYESAMI™ to Georgians suffering with Critical COVID-19.
The related NRx press release can be accessed through the following link.
https://markets.businessinsider.com/news/stoc...1030651652
RELIEF AND ADVITA CLOSE DEFINITIVE AGREEMENT FOR RELIEF TO ACQUIRE ALL OUTSTANDING SHARES OF ADVITA
Ad Hoc Announcement pursuant to Art. 53 LR,
28 July 2021
https://www.relieftherapeutics.com/newsblog/r...-of-advita
NRx also reported that the first doses of aviptadil will arrive in the Nation of Georgia within 24 hours, and discussions are underway with the Ministry of Health to provide access to ZYESAMI™ to Georgians suffering with Critical COVID-19.
The related NRx press release can be accessed through the following link.
https://markets.businessinsider.com/news/stoc...1030651652
RELIEF AND ADVITA CLOSE DEFINITIVE AGREEMENT FOR RELIEF TO ACQUIRE ALL OUTSTANDING SHARES OF ADVITA
Ad Hoc Announcement pursuant to Art. 53 LR,
28 July 2021
https://www.relieftherapeutics.com/newsblog/r...-of-advita
(0)
(0)
$MJ
